世界の原発性硬化性胆管炎治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4765
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、129ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、原発性硬化性胆管炎治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（肝移植手術、UDCA薬、PSC薬）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・原発性硬化性胆管炎治療の市場動向
・企業の競争状況、市場シェア
・原発性硬化性胆管炎治療の種類別市場規模と予測2016-2027（肝移植手術、UDCA薬、PSC薬）
・原発性硬化性胆管炎治療の用途別市場規模と予測2016-2027（病院、クリニック、その他）
・原発性硬化性胆管炎治療の北米市場規模2016-2027（アメリカ、カナダ）
・原発性硬化性胆管炎治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・原発性硬化性胆管炎治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・原発性硬化性胆管炎治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・原発性硬化性胆管炎治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Allergan、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Dr. Falk Pharma、Daewoong Pharmaceutical、Epic Pharma、Mitsubishi Tanabe Pharma、Lannett、Bruschettini、Shanghai Pharma、Grindeks、Acorda Therapeutics、Gilead Sciences、Intercept Pharmaceuticals、Shire Plc、NGM Biopharmaceuticals、Conatus Pharmaceuticals、Durect Corporation、Sirnaomics、Shenzhen HighTide Biopharmaceuticals）
・結論

Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.

Market Analysis and Insights: Global Primary Sclerosing Cholangitis Treatment Market
The global Primary Sclerosing Cholangitis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Sclerosing Cholangitis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Sclerosing Cholangitis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Sclerosing Cholangitis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Sclerosing Cholangitis Treatment market.

Global Primary Sclerosing Cholangitis Treatment Scope and Market Size
Primary Sclerosing Cholangitis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Sclerosing Cholangitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Liver Transplantation Operation
UDCA Drugs
PSC Drugs

Segment by Application
Hospital
Clinics
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2016-2027)
2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Regions
2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Primary Sclerosing Cholangitis Treatment Industry Dynamic
2.3.1 Primary Sclerosing Cholangitis Treatment Market Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2016-2021)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2020
3.5 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2022-2027)

5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2016-2027)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
6.2.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021)
6.2.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027)
6.2.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2027)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Application
6.3.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021)
6.3.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027)
6.3.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2027)
6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Country
6.4.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021)
6.4.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2016-2027)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
7.2.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2027)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application
7.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2027)
7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country
7.4.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type
8.2.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application
8.3.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region
8.4.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size (2016-2027)
9.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type
9.2.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2027)
9.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application
9.3.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2027)
9.4 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country
9.4.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type
10.2.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application
10.3.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country
10.4.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.1.5 Allergan Recent Development
11.2 Glenmark
11.2.1 Glenmark Company Details
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.2.5 Glenmark Recent Development
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Details
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.3.5 Impax Laboratories Recent Development
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.4.5 Mylan Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Details
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Details
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.6.5 Dr. Falk Pharma Recent Development
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Details
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.7.5 Daewoong Pharmaceutical Recent Development
11.8 Epic Pharma
11.8.1 Epic Pharma Company Details
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.8.5 Epic Pharma Recent Development
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Details
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.9.5 Mitsubishi Tanabe Pharma Recent Development
11.10 Lannett
11.10.1 Lannett Company Details
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.10.5 Lannett Recent Development
11.11 Bruschettini
11.11.1 Bruschettini Company Details
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.11.5 Bruschettini Recent Development
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Details
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.12.5 Shanghai Pharma Recent Development
11.13 Grindeks
11.13.1 Grindeks Company Details
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.13.5 Grindeks Recent Development
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Details
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.14.5 Acorda Therapeutics Recent Development
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Details
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.15.5 Gilead Sciences Recent Development
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Details
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.16.5 Intercept Pharmaceuticals Recent Development
11.17 Shire Plc
11.17.1 Shire Plc Company Details
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.17.5 Shire Plc Recent Development
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Details
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.18.5 NGM Biopharmaceuticals Recent Development
11.18 Conatus Pharmaceuticals
.1 Conatus Pharmaceuticals Company Details
.2 Conatus Pharmaceuticals Business Overview
.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
.5 Conatus Pharmaceuticals Recent Development
11.20 Durect Corporation
11.20.1 Durect Corporation Company Details
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.20.5 Durect Corporation Recent Development
11.21 Sirnaomics
11.21.1 Sirnaomics Company Details
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.21.5 Sirnaomics Recent Development
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Liver Transplantation Operation
Table 3. Key Players of UDCA Drugs
Table 4. Key Players of PSC Drugs
Table 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2016-2021)
Table 9. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2022-2027)
Table 11. Primary Sclerosing Cholangitis Treatment Market Trends
Table 12. Primary Sclerosing Cholangitis Treatment Market Drivers
Table 13. Primary Sclerosing Cholangitis Treatment Market Challenges
Table 14. Primary Sclerosing Cholangitis Treatment Market Restraints
Table 15. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Primary Sclerosing Cholangitis Treatment Market Share by Players (2016-2021)
Table 17. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2020)
Table 18. Ranking of Global Top Primary Sclerosing Cholangitis Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
Table 22. Date of Enter into Primary Sclerosing Cholangitis Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Allergan Company Details
Table 63. Allergan Business Overview
Table 64. Allergan Primary Sclerosing Cholangitis Treatment Product
Table 65. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 66. Allergan Recent Development
Table 67. Glenmark Company Details
Table 68. Glenmark Business Overview
Table 69. Glenmark Primary Sclerosing Cholangitis Treatment Product
Table 70. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 71. Glenmark Recent Development
Table 72. Impax Laboratories Company Details
Table 73. Impax Laboratories Business Overview
Table 74. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
Table 75. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 76. Impax Laboratories Recent Development
Table 77. Mylan Company Details
Table 78. Mylan Business Overview
Table 79. Mylan Primary Sclerosing Cholangitis Treatment Product
Table 80. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 81. Mylan Recent Development
Table 82. Teva Pharmaceuticals Company Details
Table 83. Teva Pharmaceuticals Business Overview
Table 84. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 85. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 86. Teva Pharmaceuticals Recent Development
Table 87. Dr. Falk Pharma Company Details
Table 88. Dr. Falk Pharma Business Overview
Table 89. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
Table 90. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 91. Dr. Falk Pharma Recent Development
Table 92. Daewoong Pharmaceutical Company Details
Table 93. Daewoong Pharmaceutical Business Overview
Table 94. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
Table 95. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 96. Daewoong Pharmaceutical Recent Development
Table 97. Epic Pharma Company Details
Table 98. Epic Pharma Business Overview
Table 99. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 100. Epic Pharma Recent Development
Table 101. Mitsubishi Tanabe Pharma Company Details
Table 102. Mitsubishi Tanabe Pharma Business Overview
Table 103. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
Table 104. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 105. Mitsubishi Tanabe Pharma Recent Development
Table 106. Lannett Company Details
Table 107. Lannett Business Overview
Table 108. Lannett Primary Sclerosing Cholangitis Treatment Product
Table 109. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 110. Lannett Recent Development
Table 111. Bruschettini Company Details
Table 112. Bruschettini Business Overview
Table 113. Bruschettini Primary Sclerosing Cholangitis Treatment Product
Table 114. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 115. Bruschettini Recent Development
Table 116. Shanghai Pharma Company Details
Table 117. Shanghai Pharma Business Overview
Table 118. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product
Table 119. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 120. Shanghai Pharma Recent Development
Table 121. Grindeks Company Details
Table 122. Grindeks Business Overview
Table 123. Grindeks Primary Sclerosing Cholangitis Treatment Product
Table 124. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 125. Grindeks Recent Development
Table 126. Acorda Therapeutics Company Details
Table 127. Acorda Therapeutics Business Overview
Table 128. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product
Table 129. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 130. Acorda Therapeutics Recent Development
Table 131. Gilead Sciences Company Details
Table 132. Gilead Sciences Business Overview
Table 133. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product
Table 134. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 135. Gilead Sciences Recent Development
Table 136. Intercept Pharmaceuticals Company Details
Table 137. Intercept Pharmaceuticals Business Overview
Table 138. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 139. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 140. Intercept Pharmaceuticals Recent Development
Table 141. Shire Plc Company Details
Table 142. Shire Plc Business Overview
Table 143. Shire Plc Primary Sclerosing Cholangitis Treatment Product
Table 144. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 145. Shire Plc Recent Development
Table 146. NGM Biopharmaceuticals Company Details
Table 147. NGM Biopharmaceuticals Business Overview
Table 148. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 149. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 150. NGM Biopharmaceuticals Recent Development
Table 151. Conatus Pharmaceuticals Company Details
Table 152. Conatus Pharmaceuticals Business Overview
Table 153. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 154. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 155. Conatus Pharmaceuticals Recent Development
Table 156. Durect Corporation Company Details
Table 157. Durect Corporation Business Overview
Table 158. Durect Corporation Primary Sclerosing Cholangitis Treatment Product
Table 159. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 160. Durect Corporation Recent Development
Table 161. Sirnaomics Company Details
Table 162. Sirnaomics Business Overview
Table 163. Sirnaomics Primary Sclerosing Cholangitis Treatment Product
Table 164. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 165. Sirnaomics Recent Development
Table 166. Shenzhen HighTide Biopharmaceuticals Company Details
Table 167. Shenzhen HighTide Biopharmaceuticals Business Overview
Table 168. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 169. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2016-2021) & (US$ Million)
Table 170. Shenzhen HighTide Biopharmaceuticals Recent Development
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2020 VS 2027
Figure 2. Liver Transplantation Operation Features
Figure 3. UDCA Drugs Features
Figure 4. PSC Drugs Features
Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 10. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2022-2027)
Figure 14. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2020
Figure 15. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2020
Figure 17. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2016-2027)
Figure 21. North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2016-2027)
Figure 22. North America Primary Sclerosing Cholangitis Treatment Market Share by Country (2016-2027)
Figure 23. United States Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2016-2027)
Figure 27. Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2016-2027)
Figure 28. Europe Primary Sclerosing Cholangitis Treatment Market Share by Country (2016-2027)
Figure 29. Germany Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Region (2016-2027)
Figure 39. China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Primary Sclerosing Cholangitis Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 59. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 60. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 61. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 62. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 63. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 64. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 65. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 66. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 67. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 68. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 69. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 70. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 71. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 72. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 73. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 74. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 75. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 76. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 77. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 78. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 79. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed

以下、関連資料のご紹介

世界の原発性胆汁性胆管炎治療薬市場規模・現状・予測（2021年-2027年）

Global Primary Biliary Cholangitis Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4763 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、原発性胆汁性胆管炎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オカリバ、ウルソジオール、その他）、用途別市場規模（病院、私立クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界のOAB治療市場規模・現状・予測（2021年-2027年）

Global OAB Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5902 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、OAB治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗コリン作用薬、ミラベグロン、ボトックス）、用途別市場規模（特発性過活動膀胱、神経性過活動膀胱）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の色汗症治療市場規模・現状・予測（2021年-2027年）

Global Chromhidrosis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5658 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、色汗症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アポクリン色汗症、エクリン色汗症、偽色汗症）、用途別市場規模（病院＆診療所、専門医＆皮膚科医院、その他）、主要地域別市場規模（北米、アメリカ、...

世界の多発性筋炎治療市場規模・現状・予測（2021年-2027年）

Global Polymyositis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4732 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、多発性筋炎治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、アルキル化剤、免疫グロブリン、モノクローナル抗体、コルチコステロイド）、用途別市場規模（病院、クリニック、その他）、主要地域別...

世界のアルギニン血症治療市場規模・現状・予測（2021年-2027年）

Global Argininemia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3852 2021年6月 87Pages
QYResearch社発行の本調査レポートでは、アルギニン血症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

世界の痙性斜頸治療市場規模・現状・予測（2021年-2027年）

Global Cervical Dystonia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5653 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、痙性斜頸治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ボツリヌス菌、抗コリン作用薬、ドーパミン作動薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市場規模（...

世界の認知症治療市場規模・現状・予測（2021年-2027年）

Global Dementia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4106 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、認知症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ドネペジル、メマンチン、リバスチグミン、その他）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の視神経炎治療市場規模・現状・予測（2021年-2027年）

Global Optic Neuritis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5912 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、視神経炎治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（静脈注射、経口）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界のアルギナーゼ欠損症治療市場規模・現状・予測（2021年-2027年）

Global Arginase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3851 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、アルギナーゼ欠損症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界の筋層浸潤性膀胱がん治療市場規模・現状・予測（2021年-2027年）

Global Muscle Invasive Bladder Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5259 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、筋層浸潤性膀胱がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ネオアジュバント化学療法、術後化学療法）、用途別市場規模（病院、研究所、専門クリニック）、主要地域別市場規模（北米、アメリカ、欧州...

世界の原発性胆汁性胆管炎治療薬市場規模・現状・予測（2021年-2027年） Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. There is a dire need for curative therapy for primary biliary cholangitis across the world. This is because of the recurring nature of the disease. Currently, the only cure for th…
世界の移植治療薬市場規模・現状・予測（2021年-2027年） Transplantation is the transfer (engraftment) of human cells, tissues, or organs from a donor to a recipient, with the aim of restoring function(s) in the body. Market Analysis and Insights: Global Transplantation Therapeutics Drugs Market The global Transplantation Therapeutics Drugs market size is…
世界のウイルス性肺炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Viral Pneumonia Treatment Drugs Market The global Viral Pneumonia Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data i…
世界の副鼻腔炎治療薬市場規模・現状・予測（2021年-2027年） Sinusitis is an inflammation or swelling of the tissue lining the sinuses. Market Analysis and Insights: Global Sinusitis Treatment Drugs Market The global Sinusitis Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-20…
世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Polycystic Kidney Disease Treatment Drugs Market The global Polycystic Kidney Disease Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in anal…